SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : momo-T/FIF
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: scaram(o)uche who wrote (12009)1/16/2019 11:23:45 AM
From: tuck  Read Replies (1) of 12215
 
Interesting little thread/concept on preclinical publications. This guy uses it to short questionable early stage companies. I know you don't do this, but perhaps it helps point to ones to avoid, since you to tend towards early stage companies. And I needed a place to park this where it might be seen here:

Shorting bad preclinical publications

Of course, it takes some work. But there's a raft of early stage IPOs approaching lock-up expiration to boot, where this concept could be applied profitably to separate the wheat from the chaff and then act according to one's trading style.

Don't be surprised if I come back to this with some attempts at examples and ask for a second opinion from actual SI scientists.

Cheers, Tuck
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News